Sign In
Buy TEVA
$34.43
-0.0300 (-0.0871%)
At Close: Aug 04, 2026
FTC Warns ‘Junk Patents' Could Make Drugs Like Ozempic Pricier—Here's How
01:56pm, Tuesday, 30'th Apr 2024
The Federal Trade Commission is challenging hundreds of alleged “junk” patent listings filed by several pharmaceutical companies, which regulators claim could increase prices for medications like
You Would Fire “God” As Your Portfolio Manager
04:44pm, Tuesday, 23'rd Apr 2024
Investors are growing nervous
3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
12:16pm, Thursday, 18'th Apr 2024
The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to RDY, TEVA and VTRS.
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
04:30pm, Tuesday, 09'th Apr 2024
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2024 financial results on Wednesday
Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
11:53am, Monday, 01'st Apr 2024
Teva Pharmaceutical and Viatris convinced a U.S. appeals court on Monday to revive their challenges to a patent covering a blockbuster Johnson & Johnson schizophrenia drug, giving them a new chance to
6 reasons to buy Teva Pharmaceuticals stock sooner than later
06:21am, Monday, 26'th Feb 2024
Teva Pharmaceutical Industries Ltd. NYSE: TEVA is a global pharmaceutical company in the medical sector specializing in generic and specialty medications.
Teva Pharm to stay as unified generics, branded drugmaker, CEO says
04:45am, Tuesday, 20'th Feb 2024
Teva Pharmaceutical Industries will remain a single company for both generic and branded drugs since generics help to fund research and development of its innovative medicines, Chief Executive Richard
TEVA Q4 Earnings and Revenues Surpass Estimates, Stock Up
12:56pm, Thursday, 01'st Feb 2024
TEVA reports better-than-expected fourth-quarter results, beating both earnings and sales estimates. The stock gains 3% in response.
Teva's CEO talks Q4 earnings and how he is implementing his 'pivot to growth' strategy
04:20pm, Wednesday, 31'st Jan 2024
Shares of Teva Pharmaceuticals (TEVA) are trending up as the company reported its fourth-quarter earnings, beating Wall Street expectations on both its top and bottom line. On Wednesday, the company c
Teva Pharma CEO Richard Francis on Q4 earnings
12:32pm, Wednesday, 31'st Jan 2024
Richard Francis, Teva Pharmaceuticals CEO, joins 'Money Movers' to discuss the company's recent divestiture, how easy it'll be to disentangle from part of its business, and more.
Teva Pharmaceutical Industries Ltd. (TEVA) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
11:31am, Wednesday, 31'st Jan 2024
Although the revenue and EPS for Teva Pharmaceutical Industries Ltd. (TEVA) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key me
Teva to divest active pharmaceutical ingredient business
06:33am, Wednesday, 31'st Jan 2024
Teva Pharmaceutical Industries will divest its active pharmaceutical ingredient (API) unit to focus on its core business, the world's largest generic drugs maker said on Wednesday.
Unveiling Teva Pharmaceutical Industries Ltd. (TEVA) Q4 Outlook: Wall Street Estimates for Key Metrics
10:21am, Friday, 26'th Jan 2024
Besides Wall Street's top -and-bottom-line estimates for Teva Pharmaceutical Industries Ltd. (TEVA), review projections for some of its key metrics to gain a deeper understanding of how the company mi
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
11:36am, Thursday, 25'th Jan 2024
With the ease in inflationary pressure, the Zacks Medical - Generic Drugs industry is expected to benefit from declining costs. New product launches provide some respite to AMPH, RDY and TEVA.
Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?
10:46am, Thursday, 25'th Jan 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
